News for MoonLake Immunotherapeutics Stock (MLTX)

MoonLake Immunotherapeutics Is Now Thoroughly De-Risked

Seeking Alpha • 09/28/23

These 8 Stocks Are Outperforming Nvidia In 2023

Investors Business Daily • 09/18/23

Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday

The Motley Fool • 09/12/23

The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 13%

Investors Business Daily • 09/12/23

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

GlobeNewsWire • 09/06/23

The 7 Most Promising Momentum Stocks to Own Now

InvestorPlace • 08/31/23

Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)

Seeking Alpha • 08/28/23

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

GlobeNewsWire • 08/10/23

August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge

Seeking Alpha • 07/31/23

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

GlobeNewsWire • 07/25/23

Strong Mid-Cap Insider Buys: Q2 2023

Seeking Alpha • 07/24/23

Exclusive: MoonLake Immunotherapeutics explores sale-sources

Reuters • 07/14/23

Why MoonLake Immunotherapeutics Stock Skyrocketed This Week

The Motley Fool • 06/29/23

MoonLake Immunotherapeutics Makes a Moonshot on Trials

MarketBeat • 06/28/23

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

GlobeNewsWire • 06/28/23

Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today

The Motley Fool • 06/27/23

MoonLake: Further Gains Possible With End Of 2023 Data Releases

Seeking Alpha • 06/27/23

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

GlobeNewsWire • 06/26/23

Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday

The Motley Fool • 06/26/23

Why Is MoonLake Immunotherapeutics (MLTX) Stock Up 93% Today?

InvestorPlace • 06/26/23

Why Mutual Fund Darling And Top 1% Stock MoonLake Immunotherapeutics Nearly Doubled

Investors Business Daily • 06/26/23

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

GlobeNewsWire • 06/25/23

MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks Investment Research • 05/26/23

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

GlobeNewsWire • 05/12/23

Why MoonLake (MLTX) Might Surprise This Earnings Season

Zacks Investment Research • 05/11/23